title: Enhancement in the protective qualities of gastric mucus by ebrotidine during duodenal ulcer healing.
abstract: 1. Gastric mucus from duodenal ulcer patients before and following therapy with a new antiulcer agent, ebrotidine, at 400, 600 and 800 mg dose was examined for changes in the physicochemical qualities and anti-H. pylori activity. 2. The results of physical measurements revealed that successful therapy with ebrotidine was accompanied by a 25% increase in gastric mucus viscosity, and a 20% increase in H+ retardation capacity, while its hydrophobicity increased by 11%. 3. The enhancement in the physical properties of mucus with ebrotidine therapy were also reflected in a marked (2.6-2.9-fold) increase in the proportion of the high molecular weight form of mucin. Furthermore, following therapy with ebrotidine, the gastric mucins showed a 36% higher content of sulfate as compared to that before the therapy. 4. Assays on the H. pylori aggregating titer of gastric mucin revealed that ebrotidine therapy at all three doses evoked a 4-fold increase in mucin anti-H. pylori activity. 5. The data demonstrate that duodenal ulcer therapy with ebrotidine leads to a marked improvement in the protective qualities of gastric mucus essential for the maintenance of mucosal integrity and enhances the inherent mucosal defense against H. pylori infection.
authors.affiliation: Research Center, University of Medicine and Dentistry of New Jersey, Newark, USA.
authors.forename: B L
authors.initials: BL
authors.lastname: Slomiany
authors.forename: J
authors.initials: J
authors.lastname: Piotrowski
authors.forename: J
authors.initials: J
authors.lastname: Majka
authors.forename: A
authors.initials: A
authors.lastname: Czajkowski
authors.forename: A
authors.initials: A
authors.lastname: Slomiany
authors.forename: A
authors.initials: A
authors.lastname: Gabryelewicz
mesh_terms: D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008970:Molecular Weight; D009077:Mucins / Q000737:chemistry; D009093:Mucus / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D013844:Thiazoles / Q000627:therapeutic use*; D014783:Viscosity
chemical_list: D000897:Anti-Ulcer Agents; D001557:Benzenesulfonates; D009077:Mucins; D013844:Thiazoles; C075156:ebrotidine